期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Analysis of the Efficacy of Triamcinolone Acetonide Combined with Ranibizumab in the Treatment of Fundus Diseases
1
作者 Wanqiu Jiao Jingwei Zhang +1 位作者 Ning Ma Zhigang Ma 《Journal of Clinical and Nursing Research》 2023年第6期30-35,共6页
Objective:To analyze the effect of triamcinolone acetonide combined with ranibizumab in patients with fundus diseases.Methods:100 patients with fundus diseases admitted from January 2018 to January 2023 were selected.... Objective:To analyze the effect of triamcinolone acetonide combined with ranibizumab in patients with fundus diseases.Methods:100 patients with fundus diseases admitted from January 2018 to January 2023 were selected.The patients were separated into two groups according to the random number table method,with 50 cases in the control group(treated with ranibizumab),and 50 cases in the observation group(treated with triamcinolone acetonide combined with ranibizumab).The clinical effects of both treatment regimens were compared.Results:The time taken for symptom disappearance of the observation group was shorter than that of the control group(P<0.05).The observation group had higher naked-eye visual acuity(4.18±0.89)compared to the control group.Besides,the observation group also had lower intraocular pressure(14.19±1.33 mmHg)and retinal thickness(283.14±3.29μm),with(P<0.05)compared to the control group.Moreover,the observation group had a lower adverse reaction rate and a higher quality of life(P<0.05).Conclusion:The application of triamcinolone acetonide combined with ranibizumab treatment can quickly relieve the clinical symptoms of patients with fundus disease,improve visual acuity,intraocular pressure,and retinal thickness,with low adverse reaction rate and better prognosis and quality of life. 展开更多
关键词 Intravitreal injection of ranibizumab Monoclonal antibody treatment Fundus diseases Adverse reactions Quality of life
下载PDF
Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy:a 2-year result and systematic review 被引量:1
2
作者 Meng Zhao Hai-Ying Zhou +3 位作者 Jun Xu Feng Zhang Wen-Bin Wei Ning-Pu Liu 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2017年第3期413-422,共10页
AIM:To report a cohort of patients with polypoidal choroidal vasculopathy(PCV)treated with photodynamic therapy(PDT)followed by intravitreal ranibizumab injection 24-48 h later,and to compare the results between ... AIM:To report a cohort of patients with polypoidal choroidal vasculopathy(PCV)treated with photodynamic therapy(PDT)followed by intravitreal ranibizumab injection 24-48 h later,and to compare the results between eyes with PCV treated by PDT followed by intravitreal anti-vascular endothelial growth factor(VEGF)injection and intravitreal anti-VEGF injection followed by PDT by Meta-analysis.METHODS:Retrospective study and systematic literature review. Medical records of patients with PCV who were initially treated using PDT followed by intravitreal ranibizumab injection 24-48 h after PDT and had completed at least 2y follow-up were reviewed and analyzed. Clinical data,including age,sex,best-corrected visual acuity(BCVA),fundus photograph,fluorescein angiography,indocyanine green angiography and optical coherence tomography were investigated. A systematic literature review was also conducted,and a visual outcome of studies over 1y was compared using Meta-analysis. RESULTS:A total of 52 patients were included in the study. Mean BCVA at baseline and follow-up at 1 or 2y were 0.71± 0.61,0.51±0.36 and 0.68±0.51 log MAR,respectively. The cumulative hazard rate for recurrence at 1 and 2y followup was 15.4% and 30.3% respectively. The percentage of eyes with polyps regression at 3,12 and 24 mo follow-up was 88.5%,84.6% and 67.3% respectively. A Meta-analysis based on 22 independent studies showed the overall vision improvements at 1,2 and 3y follow-up were 0.13±0.04(P〈0.001),0.12±0.03(P〈0.001),0.16±0.06(P〈0.001),respectively. The proportion of polyps regression at 1y follow-up was 64.6%(95%CI:51.5%,77.7%,P〈0.001)in 434 eyes treated by intravitreal anti-VEGF agents beforePDT and 76.0%(95%CI:64.8%,87.3%,P=0.001)in 199 eyes treated by intravitreal anti-VEGF agents after PDT. CONCLUSION:Intravitreal ranibizumab injection 24-48 h following PDT effectively stabilizes visual acuity in the eye with PCV. PDT followed by intravitreal anti-VEGF agents may contribute to a relatively higher proportion of polyps' regression as compared to that of intravitreal anti-VEGF before PDT. 展开更多
关键词 polypoidal choroidal vasculopathy photodynamic therapy intravitreal ranibizumab injection Metaanalysis
下载PDF
Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration 被引量:6
3
作者 Bekir Kücük Sibel Kadayifcilar Bora Eldem 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2018年第4期645-649,共5页
AIM: To investigate the long-term visual and anatomical outcomes of patients who underwent intravitreal ranibizumab monotherapy to treat neovascular age-related macular degeneration(AMD) and followed-up for at leas... AIM: To investigate the long-term visual and anatomical outcomes of patients who underwent intravitreal ranibizumab monotherapy to treat neovascular age-related macular degeneration(AMD) and followed-up for at least 2 y.METHODS: A total of 74 eyes of 74 patients who underwent ranibizumab monotherapy for neovascular AMD were included in this retrospective study.RESULTS: The average patient age was 72.1±6.5(range, 57-85)y, the average follow-up time 46.2±13.1(range, 24-75)mo, and the average number of visits 24.1±9.5(range, 8-48). The mean number of injections in year 1 was 4.5, 1.6 in year 2, 0.9 in year 3, 0.4 on year 4, and 0.1 in the following years. Within the entire follow-up period, the mean number of injections was 7.6±4.4(range, 2-21). The mean visual acuity was 48.1±15(range, 15-76) letters at baseline and 45.7±19(range, 7-75) at year 5. The mean central macular thickness was 303±78(range, 178-552) μm at baseline and 251±51(range, 138-359) μm at year 5. Scars developed in 47(63.5%) eyes at the end of the follow-up period, and atrophy was evident in 6(8.1%) eyes.CONCLUSION: Ranibizumab monotherapy can stabilize visual acuity for a mean period of 4 y in patients with neovascular AMD. 展开更多
关键词 intravitreal injection neovascular age-related macular degeneration ranibizumab
下载PDF
Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness 被引量:8
4
作者 Shi Xuehui Wei Wenbin Zhang Cong 《Chinese Medical Journal》 SCIE CAS CSCD 2014年第12期2279-2285,共7页
Background Photodynamic therapy (PDT) has been recommended as a main treatment for idiopathic choroidal neovascularization (I-CNV).But the visual results of PDT were inconsistent and variable,and PDT may bring sev... Background Photodynamic therapy (PDT) has been recommended as a main treatment for idiopathic choroidal neovascularization (I-CNV).But the visual results of PDT were inconsistent and variable,and PDT may bring severe damage to the retinal pigment epithelium and choriocapillaries.In recent years,intravitreal ranibizumab therapy,showing favorable visual outcomes,has developed as an advanced treatment for choroidal neovascularization (CNV).Although both methods have been reported to be effective in treating I-CNV,there is no detailed comparative report between the two methods.This study aimed to compare visual outcomes,retinal and choroidal thickness between intravitreal ranibizumab therapy and PDT in the treatment of I-CNV,and investigate the correlation of visual outcomes with retinal and choroidal thickness in each of the two groups.Methods Thirty-seven eyes of 37 patients with I-CNV were involved in this study; 19 eyes were treated with intravitreal ranibizumab therapy and 18 eyes were treated with PDT.The best corrected visual acuity (BCVA) was recorded before and at each follow-up visit after treatments (IogMAR).Enhanced-depth imaging optical coherence tomography (EDI-OCT) was used to evaluate the retinal structural changes,and to measure central retinal thickness (CRT) and central choroidal thickness (CCT).Results Mean BCVA was 0.64±0.27 in PDT group and 0.69±0.22 in ranibizumab group at baseline (P=0.55).When compared with the baseline,mean BCVA in PDT group was improved significantly at 3-month after PDT (0.41±0.16,P=0.002),then changed little (0.42±0.25 at 12-month,P=0.88).Whereas mean BCVA in Ranibizumab group was improved significantly at each follow-up visit.It improved much more obviously in the first month and then remained stable.The mean BCVA in the ranibizumab group was significantly better at each follow-up visit than that in PDT (P <0.05).When compared with the baseline,mean CRT in PDT group decreased significantly since 3-month visit,whereas mean CRT in ranibizumab group decreased significantly from 1-month visit.Mean CRT at 1-month and 3-month decreased much more in ranibizumab group than that in PDT group,almost in the same period as BCVA improving.When compared with the baseline,mean CCT did not change significantly at each follow-up visit in each group (P >0.05).The CCT difference was not statistically significant between the two groups at each same time visit (P >0.05).Mean BCVA was correlated with CRT,but was not correlated with CCT.Conclusions Both intravitreal ranibizumab therapy and PDT are effective for the treatment of I-CNV.It is obvious that ranibizumab therapy is significantly superior to PDT in improving BCVA and decreasing CRT.CRT decreases much more rapidly in ranibizumab group than in PDT group,simultaneously with visual improvement.CRT reduction has significant correlation with the visual outcomes in the recovery of I-CNV,whereas BCVA prognosis may have no correlation with CCT.CCT is not changed significantly after each of the treatments.Both PDT and ranibizumab therapy may have no significant effect on choroid. 展开更多
关键词 idiopathic choroidal neovascularization intravitreal ranibizumab injection photodynamic therapy visual outcome retinal thickness choroidal thickness
原文传递
Retinoschisis and intravitreal ranibizumab treatment for myopic choroidal neovascularization 被引量:3
5
作者 Huang Jianfeng Chen Tong Lu Yingyi Long Li Dai Hong 《Chinese Medical Journal》 SCIE CAS CSCD 2014年第11期2053-2057,共5页
Background Intravitreal ranibizumab injection is effecitve on treating myopic CNVs,but it could be a risk factor for developing more severe retinoschisis in eyes with preexisted retinoschisis and epiretinal membrane.T... Background Intravitreal ranibizumab injection is effecitve on treating myopic CNVs,but it could be a risk factor for developing more severe retinoschisis in eyes with preexisted retinoschisis and epiretinal membrane.This study aimed to explore the incidence and features of retinoschisis after intravitreal ranibizumab injection for myopic choroidal neovascularization.Methods Eighty-three eyes of 81 patients with choroidal neovascularization secondary to pathologic myopia were treated with intravitreal ranibizumab injection.The best corrected visual acuity and optical coherence tomography (OCT) images were recorded at baseline and every month thereafter.Central retina thickness and maximal retina thickness were measured.The subjects were divided into three groups.Eleven eyes that had retinoschisis and epiretinal membrane were in group 1,six eyes that had simple epiretinal membrane were in group 2,and 66 eyes that had neither retinoschisis nor epiretinal membrane were in group 3.Six contralateral eyes in group 1 which had retinoschisis and epiretinal membrane but were not treated with intravitreal ranibizumab injection were set as the control group.Results Seven of the 11 eyes in group 1 developed more severe retinoschisis,the mean maximal retinal thickness increased from (380.28±90.13) to (467.00±70.20) μm (P 〈0.05).The retinoschisis of all 6 eyes of the control group did not aggravate.Compared with the control group,the aggravation ratio of retinoschisis increased significantly (P 〈0.05).No new onset of retinoschisis took place in group 2 and group 3.Conclusion Intravitreal ranibizumab injection may be a risk factor for aggravation of retinoschisis in eyes with preexisted retinoschisis and epiretinal membrane. 展开更多
关键词 epiretinal membrane intravitreal ranibizumab injection myopic choroidal neovascularization OCT pathologic myopia RETINOSCHISIS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部